On September 23, GENSCRIPT BIO rose 3.11% in regular trading, trading at HK$41.46/share, with turnover of HK$387 million, extending its recent rally fueled by multiple catalysts.

On the news front, the company announced on September 21 that its board lot size will be halved from 2,000 shares to 1,000 shares effective October 14, reducing the minimum trading threshold from approximately HK$82,800 to HK$41,400 per lot based on the closing price of HK$41.40. Meanwhile, the company recently disclosed a partnership with Eli Lilly's AI-driven drug discovery platform Lilly TuneLab, under which GENSCRIPT BIO will provide wet-lab services to participating enterprises, translating AI predictions into biological validation data. Everbright Securities maintained a Buy rating, noting AI-driven protein orders are expected to sustain triple-digit percentage growth in the second half and beyond. The company also completed a placement of approximately 77.13 million shares at HK$30.50 each, raising net proceeds of approximately HK$2.327 billion, with roughly 70% earmarked for expanding its AIDD platform capacity and infrastructure.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)